Cargando…

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy

Detalles Bibliográficos
Autores principales:	Marcelin, AG, Charpentier, C, Wirden, M, Descamps, D, Calvez, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112909/ http://dx.doi.org/10.1186/1758-2652-13-S4-P133

Ejemplares similares

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Darunavir pharmacokinetics throughout pregnancy and postpartum
por: Lambert, John, et al.
Publicado: (2014)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort
por: Chaussade, Hélène, et al.
Publicado: (2020)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2012)

Administration of darunavir tablets in patients with difficulties in swallowing – two case reports
por: Scholten, S, et al.
Publicado: (2010)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
por: Sension, M, et al.
Publicado: (2010)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2020)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
por: Bedimo, Roger J., et al.
Publicado: (2014)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Appropriate clinical use of darunavir 800 mg
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Molecular designing and in silico evaluation of darunavir derivatives as anticancer agents
por: Mahto, Manoj kumar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_03chutmehgntoqooec9fvearkf